Skip to content

Advertisement

  • Research
  • Open Access

Sensitization profile in patients with respiratory allergic diseases: differences between conventional and molecular diagnosis (a cross-sectional study)

Clinical and Molecular Allergy201917:8

https://doi.org/10.1186/s12948-019-0112-4

©  The Author(s) 2019

  • Received: 12 February 2019
  • Accepted: 28 March 2019
  • Published:

Abstract

Background

Component-resolved diagnosis (CRD) allows to identify single molecular allergen components, and constitutes a routine practice in many allergy units. However, skin prick test (SPT) remains the technique of choice in many otorhinolaryngology departments, thus increasing the risk of using inadequate immunotherapies in patients with respiratory allergies. This study aimed to compare sensitization profiles determined by SPT and CRD in patients with respiratory allergy, and to explore the relationship between sensitization and type and severity of the respiratory disease.

Methods

Cross-sectional, multicenter study of patients admitted to the Otorhinolaryngology Department due to symptoms of respiratory allergy. Extracts from various house dust mites, pollens, and molds were tested by SPT, whereas IgE against the corresponding antigens were measured by CRD.

Results

The analysis included 101 patients. The sensitization profile obtained by SPT had low agreement with that of CRD, particularly to dust mite allergens (Dermatophagoides sp.) and pollens (Plantago lanceolata, Olea europaea, and Cupressus sempervirens). While SPT did not show any significant relationship between sensitization and type/severity of the respiratory disease, CRD allowed to associate Der p 1, Der f 1 and Lep d 2 sensitizations with asthma, and Der p 2, Der f 2 and Lep d 2 sensitizations with more severe symptoms of allergic rhinitis.

Conclusions

Compared with SPT, CRD enables to describe a more accurate sensitization profile and to identify associations between symptoms and specific antigens. The routine use of CRD in an otorhinolaryngology setting may benefit the management of patients with respiratory allergy.

Trial registration IB 3108/15 (Retrospectively registered)

Keywords

  • Allergens
  • Allergic rhinitis
  • Asthma
  • Component-resolved diagnosis
  • Skin prick test
  • Polysensitization

Background

Respiratory allergies, particularly allergic rhinitis and asthma, are amongst the most common allergies in industrialized areas. They constitute a major public health and economic problem worldwide because of their prevalence, morbidity, and impact on quality of life [1–3]. Of all allergens that can elicit respiratory allergic reactions, grass pollen and house dust mites have been identified as the most prevalent [4, 5]. However, many patients are sensitized to various allergic sources, either as a result of multiple allergic responses or due to the presence of cross-reactants or panallergens [6]. This phenomenon often hinders the correct identification of the allergen source, which may ultimately lead to an inadequate diagnosis or treatment of the allergic disease [7–9].

The diagnosis of allergic diseases has been traditionally based on patient anamnesis, supported by skin prick test (SPT) and/or the identification of serum IgE in whole allergen extracts. Both methods are suitable for detecting reactivity against allergen extracts but fail to identify the specific disease-eliciting molecules. The development of the component-resolved diagnosis (CRD), also known as molecular diagnosis, has allowed to identify single molecular allergen components responsible for sensitization [10]. This feature, which allows to distinguish symptom-eliciting allergens from those attributable to cross-reactivity, has become particularly relevant since the advent of allergen-specific immunotherapy [10–12]. While CRD has been increasingly established as routine practice in many allergy units, SPT remains the technique of choice in many otorhinolaryngology departments because of its lower cost, thus increasing the risk of using inadequate immunotherapies in patients with respiratory allergies [7, 13].

Subjects living in areas with high allergy burden (e.g., Mediterranean countries) are more prone to sensitizations to minor allergens; therefore, these areas often show a higher prevalence of polysensitized patients. In this scenario, the identification of disease-eliciting molecules provided by CRD becomes even more relevant in terms of using accurate immunotherapies. In this cross-sectional study, we compared sensitization profiles determined by SPT and CRD in patients with respiratory allergy from a Mediterranean area and explored the relationship between sensitization and type and severity of the respiratory disease.

Methods

Study design and patients

This was a cross-sectional study of consecutive patients admitted to the otorhinolaryngology department of three hospitals in the Balearic Islands (Spain) due to symptoms of respiratory allergy between October 2012 and November 2013. The inclusion was restricted to patients of both sexes, aged between 7 and 60 years, who had been living in the same area for at least 5 years, had experienced symptoms of a respiratory allergic disease (i.e., rhinitis, asthma or both) for at least 2 years and had a positive reaction to an allergen as determined by SPT. Patients who received immunotherapy within 5 years prior to admission or who had no diagnostic tests performed were excluded from the dataset.

Variables and endpoints

Demographic and clinical characteristics included age, sex, time from symptoms onset to diagnosis, type of respiratory allergic disease (rhinitis, asthma or rhinitis with concomitant asthma), frequency of symptoms (perennial or seasonal), and severity of the allergic disease, which was rated as mild or moderate-to-severe, based on the Spanish guidelines on the management of asthma (GEMA) [14, 15] and allergic rhinitis with impact on asthma (ARIA) [16]. Other clinical data included concomitant food allergies, and personal and/or family history of allergy. Allergen sensitization was determined using both SPT and CRD. Patients sensitized to more than one extract (SPT) or to specific IgE of more than one species (CRD) were considered polysensitized.

Skin prick test, performed according to the European Academy of Allergy and Clinical Immunology guidelines [17], was considered positive if wheals and flares were observed within 15 min, and wheal mean diameter was ≥ 3 mm. The following extracts were tested by SPT: House dust mites Dermatophagoides pteronyssinus, Dermatophagoides farinae, and Lepidoglyphus destructor; pollens Olea europaea, Artemisia vulgaris, Plantago lanceolata, Platanus hispanica, Parietaria judaica, Salsola kali, Cupressus sempervirens, and grass mixture; molds Alternaria alternata. Panallergen profilins, polcalcins, non-specific lipid transfer proteins (nsLTPs), and tropomyosins were also analyzed. Histamine and saline solution were used as positive and negative controls, respectively. Allergen extracts were provided by ALK-Abelló, S.A. (Madrid, Spain).

Allergen-specific IgE was quantified using chemiluminescent acridinium on the ADVIA Centaur platform (Bayer HealthCare LLC, Diagnostics Division, Tarrytown, NY, USA) as described by Petersen et al. [18]. CRD was considered positive when binding values exceeded 0.35 kU/L. The CRD analysis screened the presence of specific IgE against the following molecules: Der p 1 and 2, Der f 1 and 2, and Lep d 2; Ole e 1 and 9, Art v 1, Pla l 1, Phl p 1 and 5, Pla a 1 and 2, Par j 2, Sal k 1, Cup s 1;Alt a 1; Pho d 2, Che a 3, Pru p 3, Der p 10, and Pen a 1.

Statistics

Quantitative variables are described as mean and standard deviation (SD) or as median and interquartile range (IQR), whereas categorical variables are presented as frequencies and percentages. Differences between groups (according to type and severity of the disease, frequency of symptoms, diagnostic method) were analyzed using the Fisher exact test or the non-parametric Wilcoxon test. Concordance between SPT and CRD methods was assessed by Cohen’s kappa coefficient (κ). Associations between demographic and clinical factors and the most prevalent sensitizations were determined by logistic regression analyses, with age, time from onset of symptoms to diagnosis, type and severity of the disease and concomitant food allergies as the independent variables. The threshold for statistical significance was established at a two-sided alpha value of 0.05. All statistical analyses were performed using the SAS 9.3 software.

Results

Characteristics of study patients

The analysis included 101 patients, whose demographic and clinical characteristics are summarized in Table 1. Time from onset of respiratory symptoms to diagnosis ranged from 1 to 30 years, with no differences regarding the frequency of symptoms: the mean (SD) for patients with perennial and seasonal symptoms was 7.7 (6.6) and 10.6 (8.0) years, respectively (p = 0.092). The most common allergic disease was rhinitis alone, followed by rhinitis with asthma. Asthma alone was present only in two patients (2%); therefore, for subsequent analyses, these patients were included in a group encompassing all patients with asthma, either alone or with concomitant rhinitis.
Table 1

Baseline characteristics of study patients (N = 101)

Demographic characteristics

 Age (years), mean (SD)

28.0 (14.6)

 Age groups, No. (%)

  Children (≤ 14 years)

28 (27.7)

  Adults (> 14 years)

73 (72.3)

 Gender, No. (%)

  Female

48 (47.5)

  Male

53 (52.5)

Clinical characteristics

 Time from onset of symptoms to diagnosis (years), mean (SD)

8.6 (7.1)

 Frequency of symptoms, No. (%)

  Perennial

69 (68.3)

  Seasonal

32 (31.7)

 Respiratory allergic diseasea, No. (%)

  Rhinitis

74 (74.7)

  Asthma

2 (2.0)

  Rhinitis and asthma

23 (23.2)

 Severity of rhinitis, No. (%)

  Mild intermittent

28 (29.5)

  Mild persistent

31 (32.6)

  Moderate-severe intermittent

7 (7.4)

  Moderate-severe persistent

29 (30.5)

 Severity of asthma, No. (%)

  Mild intermittent

14 (56.0)

  Mild persistent

4 (16.0)

  Moderate intermittent

0 (0.0)

  Moderate persistent

7 (28.0)

 Food allergy, No. (%)

7 (6.9)

 History of previous allergy, No. (%)

9 (9.0)

 Family history of allergy, No. (%)

41 (41.0)

aCalculated over 99 patients

Sensitization profile

Table 2 shows the sensitization profiles obtained with each diagnostic method. Most prevalent sensitizations, present in more than 20% of patients, were to D. pteronyssinus (Der p 1 and 2), D. farinae (Der f 1 and 2), L. destructor (Lep d 2), Olea europaea (Ole e 1), and Phleum pratense (Phl p 1) allergens. The percentage of sensitized patients was significantly higher with SPT than CRD for Der p 1 and 2, Der f 1 and 2, Lep d 2, Ole e 1, Pla l 1, and Sal k 1. However, Alt a 1 and Pru p 3 showed a lower percentage of sensitized subjects when SPT was used compared with CRD. Overall, 91 (93.8%) and 72 (79.1%) patients were polysensitized according to SPT and CRD tests, respectively. The results regarding the quantitative determination of allergen-specific IgE are summarized in Additional file 1: Table S1.
Table 2

Profile of sensitization regarding the diagnostic method, No (%)

 

SPT

CRD

p

House dust mites

 Dermatophagoides pteronyssinus

69 (68.3)

 

0.031

  Der p 1

 

44 (44.4)

  Der p 2

 

53 (53.5)

  Der p 1 or 2

 

58 (58.6)

 Dermatophagoides farinae

70 (69.3)

 

0.021

  Der f 1

 

41 (41.4)

  Der f 2

 

52 (52.5)

  Der f 1 or 2

 

59 (59.6)

 Lepidoglyphus destructor

42 (41.6)

 

< 0.001

  Lep d 2

 

21 (21.2)

Pollens

 Olea europaea

57 (56.4)

 

0.019

  Ole e 1

 

43 (44.3)

  Ole e 9

 

2 (2.0)

 Artemisia vulgaris

8 (7.9)

 

1.000

  Art v 1

 

9 (9.2)

 Plantago lanceolata

25 (24.8)

 

< 0.001

  Pla l 1

 

5 (5.1)

 Mixture of grasses

45 (44.6)

 

0.302

  Phl p 1

 

34 (34.3)

  Phl p 5

 

12 (12.1)

  Phl p 1 or 5

 

38 (38.4)

 Platanus hispanica

9 (8.9)

 

0.754

  Pla a 1 + 2

 

6 (6.1)

 Parietaria judaica

18 (17.8)

 

0.754

  Par j 2

 

16 (16.3)

 Salsola kali

10 (9.9)

 

0.039

  Sal k 1

 

3 (3.0)

 Cupressus sempervirens

15 (14.9)

 

0.125

  Cup s 1

 

9 (9.2)

Molds

 Alternaria alternata

12 (11.9)

 

0.039

  Alt a 1

 

18 (18.2)

Panallergens

 Profilins

3 (3.0)

 

0.500

  Pho d 2

 

1 (1.0)

 Polcalcins

5 (5.0)

 

0.125

  Che a 3

 

1 (1.0)

 LTPs

4 (4.0)

 

0.031

  Pru p 3

 

10 (10.1)

 Tropomyosins

NA

 

NA

  Der p 10

 

3 (3.0)

  Pen a 1

 

4 (4.0)

p values in italics correspond to significant differences at a bilateral alpha value of 0.05

CRD component-resolved diagnostics, LTPs lipid transfer proteins, NA not available, SPT skin prick test

Cohen’s kappa of SPT vs. CRD for allergens with significant differences in the sensitization profile revealed low agreement between both diagnosis methods: κ = 0.12 (95% CI − 0.10, 0.35) for D. pteronyssinus vs. Der p 1 and 2; κ = − 0.05 (95% CI − 0.12, 0.01) for D. farinae vs. Der f 1 and 2;κ = 0.05 (95% CI − 0.08, 0.19) for L. destructor vs. Lep d 2; κ = − 0.01 (95% CI − 0.20, 0.17) for O. europaea vs. Ole e 1 and 9; and κ = 0.07 (95% CI − 0.09, 0.23) for P. lanceolata vs. Pla l 1 and 2. Cohen’s kappa could not be determined for Sal k 1 and Alt a 1.

Association between allergens and diseases

Table 3 summarizes the association between allergen sensitizations and type of respiratory allergic disease. SPT did not reveal significant associations, except for the extract of P. lanceolata, the sensitization to which was more frequent in patients with rhinitis than those with asthma (with or without concomitant rhinitis). On the other hand, sensitization to house dust mite allergens Der p 1, Der f 1 and Lep d 2 were significantly more frequent in patients with asthma (with or without concomitant rhinitis) compared to patients with rhinitis alone (Table 3).
Table 3

Associations between allergens and disease diagnosed by SPT and CRD

 

SPT

CRD

Asthmaa (N = 25)

Rhinitis (N = 74)

p

Asthmaa (N = 25)

Rhinitis (N = 74)

p

House dust mites

 Dermatophagoides pteronyssinus

19 (95.0)

49 (94.2)

1.000

   

  Der p 1

   

15 (65.2)

28 (37.8)

0.037

  Der p 2

   

16 (69.6)

36 (48.6)

0.118

 Dermatophagoides farinae

19 (100.0)

50 (96.2)

1.000

   

  Der f 1

   

15 (65.2)

25 (33.8)

0.010

  Der f 2

   

15 (65.2)

36 (48.6)

0.232

 Lepidoglyphus destructor

14 (100)

27 (87.1)

0.294

   

  Lep d 2

   

10 (43.5)

10 (13.5)

0.004

Pollens

 Olea europaea

17 (94.4)

38 (92.7)

1.000

   

  Ole e 1

   

13 (59.1)

28 (38.4)

0.106

  Ole e 9

   

1 (4.4)

1 (1.4)

0.420

 Artemisia vulgaris

1 (50.0)

7 (77.8)

0.491

   

  Art v 1

   

1 (4.4)

8 (11.0)

0.710

 Plantago lanceolata

4 (57.1)

21 (95.5)

0.034

   

  Pla l 1

   

0 (0.0)

5 (6.8)

0.607

 Phleum pratense

12 (92.3)

32 (100)

0.289

   

  Phl p 1

   

8 (34.8)

25 (33.8)

0.871

  Phl p 5

   

1 (4.4)

11 (14.9)

0.374

 Platanus hispanica

4 (100.0)

5 (83.3)

1.000

   

  Pla a 1 + 2

   

1 (4.4)

4 (5.4)

1.000

 Parietaria judaica

3 (100.0)

15 (93.8)

1.000

   

  Par j 2

   

4 (17.4)

12 (16.4)

1.000

 Salsola kali

1 (100.0)

9 (100.0)

–

   

  Sal k 1

   

0 (0.0)

3 (4.1)

1.000

 Cupressus sempervirens

4 (100.0)

11 (91.7)

1.000

   

  Cup s 1

   

2 (9.1)

7 (9.5)

1.000

Molds

 Alternaria alternata

3 (100.0)

9 (100.0)

–

   

  Alt a 1

   

3 (13.0)

15 (20.3)

0.801

Panallergens

 Profilins

  Pho d 2

2 (66.7)

1 (33.3)

1.000

   

 Polcalcins

  Che a 3

0 (0.0)

5 (83.3)

0.286

   

 LTPs

  Pru p 3

1 (50.0)

3 (100.0)

0.400

   

 Tropomyosins

  Der p 10

   

1 (4.5)

2 (2.7)

0.041

  Pen a 1

   

1 (4.4)

3 (4.1)

1.000

p values in italics correspond to significant differences at a bilateral alpha value of 0.05

Positive sensitizations. No. (%)

CRD component-resolved diagnostics, LTPs lipid transfer proteins, NA not available, SPT skin prick test

aWith or without concomitant rhinitis

When analyzing disease severity regarding sensitization to specific molecules, sensitization to Der p 2, Der f 2, and Lep d 2 appeared to be associated with moderate-to-severe rhinitis (Table 4). This trend was not observed in the corresponding primary antigens of Dermatophagoides sp. Der p 1 and Der f 1.
Table 4

Associations between allergens and severity disease diagnosed by component-resolved diagnostics

 

Asthmaa

Rhinitis

Mild (N = 18)

Moderate-severe (N = 7)

p

Mild (N = 59)

Moderate-severe (N = 36)

p

House dust mites

 Der p 1

11 (68.8)

4 (57.1)

0.657

25 (43.1)

17 (47.2)

0.831

 Der p 2

12 (75.0)

4 (57.1)

0.626

25 (43.1)

26 (72.2)

0.010

 Der f 1

11 (68.8)

4 (57.1)

0.657

23 (39.7)

16 (44.4)

0.672

 Der f 2

12 (75.0)

3 (42.9)

0.182

25 (43.1)

25 (69.4)

0.019

 Lep d 2

7 (43.8)

3 (42.9)

1.000

7 (12.1)

12 (33.3)

0.018

Pollens

 Ole e 1

9 (60.0)

4 (57.1)

1.000

25 (43.1)

14 (41.2)

1.000

 Ole e 9

1 (6.3)

0 (0.0)

1.000

1 (1.7)

1 (2.8)

1.000

 Art v 1

1 (6.3)

0 (0.0)

1.000

5 (8.8)

4 (11.1)

0.731

 Pla l 1

0 (0.0)

0 (0.0)

–

2 (3.4)

3 (8.3)

0.368

 Phl p 1

7 (43.8)

1 (14.3)

0.345

17 (29.3)

16 (44.4)

0.183

 Phl p 5

1 (6.3)

0 (0.0)

1.000

6 (10.3)

5 (13.9)

0.744

 Pla a 1 + 2

0 (0.0)

1 (14.3)

0.304

4 (6.9)

1 (2.8)

0.646

 Par j 2

2 (12.5)

2 (28.6)

0.557

8 (14)

7 (19.4)

0.567

 Sal k 1

0 (0.0)

0 (0.0)

–

1 (1.7)

2 (5.6)

0.556

 Cup s 1

1 (6.3)

1 (16.7)

0.480

6 (10.5)

3 (8.3)

1.000

Molds

 Alt a 1

2 (12.5)

1 (14.3)

1.000

9 (15.5)

9 (25.0)

0.289

Panallergens

 Pho d 2

      

 Che a 3

      

 Pru p 3

      

 Der p 10

0 (0.0)

1 (16.7)

0.273

0 (0.0)

2 (5.6)

0.147

 Pen a 1

1 (6.3)

0 (0.0)

1.000

2 (3.4)

2 (5.7)

0.630

p values in italics correspond to significant differences at a bilateral alpha value of 0.05

Positive sensitizations, No. (%)

aWith or without concomitant rhinitis

Demographic and clinical factors influencing sensitization

The results of the multivariate analysis to predict sensitization to each of the most prevalent antigens based on clinical and demographic characteristics are summarized in Table 5. The analysis failed to yield a multivariate model to predict sensitization to plant antigens Ole e 1 and Phl p 1. On the other hand, either the type or severity of the disease significantly contributed to sensitization toall house dust mite allergens included in the analysis (Table 5).
Table 5

Factors associated with the sensitization to allergens

 

Der p 1

Der p 2

Der f 1

Der f 2

Lep d 2

Ole e 1

Phl p 1

OR (95% CI)

p

OR (95% CI)

p

OR (95% CI)

p

OR (95% CI)

p

OR (95% CI)

p

OR (95% CI)

p

OR (95% CI)

p

Age

0.47 (0.19–1.15)

0.097

0.65 (0.27–1.58)

0.339

0.48 (0.20–1.17)

0.107

0.75 (0.31–1.81)

0.523

0.44 (0.16–1.20)

0.107

0.46 (0.19–1.14)

0.093

2.44 (0.88–6.79)

0.086

Time from onset of symptoms to diagnosis

1.04 (0.98–1.0)

0.184

1.03 (0.97–1.09)

0.302

1.02 (0.97–1.08)

0.455

1.04 (0.98–1.10)

0.227

0.98 (0.91–1.05)

0.510

1.02 (0.96–1.07)

0.590

1.04 (0.98–1.10)

0.194

Disease

2.87 (1.07–7.20)

0.036

2.26 (0.83–6.19)

0.112

3.43 (1.27–9.26)

0.015

1.85 (0.69–4.93)

0.220

5.33 (1.83–15.6)

0.002

2.14 (0.80–5.74)

0.129

1.12 (0.41–3.02)

0.823

Severity

1.47 (0.62–3.50)

0.379

4.00 (1.62–9.89)

0.003

1.57 (0.66–3.74)

0.307

4.00 (1.62–9.89)

0.003

5.98 (1.76–20.3)

0.004

1.07 (0.45–2.56)

0.877

2.08 (0.86–5.06)

0.106

Concomitant food allergy

2.72 (0.47–15.6)

0.262

0.88 (0.17–4.58)

0.877

3.11 (0.54–7.9)

0.203

0.44 (0.08–2.52)

0.355

1.92 (0.33–11.3)

0.470

7.16 (0.80–63.8)

0.078

0.36 (0.04–3.19)

0.357

p values in italics correspond to significant differences at a bilateral alpha value of 0.05

CI confidence interval, OR odds ratio

Discussion

In this cross-sectional study, we found that the sensitization profile of patients with respiratory allergy obtained by the traditional SPT has low agreement with that of CRD, particularly to dust mite allergens and pollens, such as P. lanceolata, O. europaea, and C. sempervirens. Furthermore, whereas SPT failed to reflect a significant relationship between sensitization and type/severity of the respiratory disease, CRD allowed to identify Der p 1, Der f 1 and Lep d 2 as antigens more frequently associated with asthma, and Der p 2, Der f 2 and Lep d 2 as antigens associated with more severe symptoms in patients with allergic rhinitis.

The low agreement between SPT and CRD observed in our analysis is consistent with that reported by previous authors [19, 20]. One of the major consequences of inconsistency in sensitization profiles is the inaccurate prescription of immunotherapy for patients with respiratory symptoms. In this regard, some authors have observed that the choice of immunotherapy may vary in about 55% of cases after comparing SPT and CRD sensitization profiles [7, 13] and that respondent rates increase when immunotherapy is used based on CRD results [9]. In this study, the number of sensitizations diagnosed by CRD was generally lower than those identified by SPT, being P. lanceolata the allergen that showed the greater difference (prevalence was 80% lower with CRD than with SPT). This finding was in line with that reported by Orovitg et al. [20]. and confirms Pla l 1 as a minor allergen eliciting respiratory allergic diseases in Mediterranean areas. Although this significant difference in sensitization to P. lanceolata could be attributed to the presence of panallergens (e.g., profilin), the small number of patients sensitized to panallergens in our study prevented further analyses in this regard. Other pollens with a strong presence in Mediterranean areas, such as Olea sp. [21], followed the same trend, albeit in a lesser extent. Of note, the differences between SPT and CRD for Olea sp. pollens found in our cohort were similar than those reported by previous authors in areas with higher prevalence of these pollens [20, 22]. Unlike plant antigens, the proportion of patients sensitized to LTPs (Pru p 3) and A. alternata were higher with CRD than SPT. Although our analysis does not allow us to draw strong conclusions in this regard, the cross-reactivity described for Art v 3 and Pru p 3 may have contributed to this observation [20].

The association between sensitization to specific allergens and the occurrence of respiratory diseases such as asthma and rhinitis has motivated the use of immunotherapy in those patients [23, 24]. In fact, allergen-specific immunotherapy is currently the only causal treatment for allergic rhinitis that can reduce its symptoms and the need for medical therapies [25]. However, in routine clinical practice, these therapies are often based on SPT diagnoses, assuming sensitization to main allergens. In our cohort, sensitization profiles determined by SPT did not reveal significant a relationship between sensitization and either the type of respiratory allergy or symptom severity. Conversely, CRD allowed to associate sensitizations to Der p 1, Der f 1 and Lep d 2 with asthma (with or without concomitant rhinitis), and sensitizations to Der p 2, Der f 2 and Lep d 2 with moderate-to-severe diseases in patients with rhinitis. Consistently with this finding, the multivariate analysis showed that the type of disease significantly contributed to sensitization to group 1 (Der p 1 and Der f 1) house dust mite allergens, whereas the severity of the disease significantly influenced sensitization to group 2 (Der p 2 and Der f 2) house dust mite allergens; sensitization to Lep d 2 was associated with both the type and severity of the disease. Similar relationships have been reported between various pollens and the type of respiratory disease [22, 26, 27]; however, to our knowledge, this is the first study showing a relationship between disease type/severity and house dust mite allergens. Although evidence regarding these specific relationships is still weak, consistent findings that specific antigens are associated with clinical characteristics of the respiratory disease strengthen the importance of using CRD to assess the sensitization profile of patients with respiratory allergy.

The main limitation of our study was its cross-sectional design, which restricted data collection to a particular period of the year for each patient, thus losing sight of changes in sensitization profiles caused by variations in antigen prevalence throughout the seasons. Although most patients in our cohort had perennial symptoms (and, therefore, were expected to show consistent sensitization profiles throughout the year), sensitization to pollens has a high seasonal variability in our area [21]. Another limitation of our results was the low prevalence of panallergens found in our study cohort. The presence of these allergens, which is commonly higher in other studies [20, 22, 27], has been considered a key benefit of CRD and may increase the differences between the two types of diagnosis.

Conclusions

Our results emphasize the limitations of SPT to determine sensitization profiles of patients with respiratory allergy in an otorhinolaryngology setting. Although the relationship between symptoms and specific antigens is still poorly understood, the ability of CRD to depict more accurate sensitization profiles and identify candidates to symptom-triggering antigens indicates that the routine use of CRD in this setting may provide remarkable benefits for the management of patients with respiratory allergy. The assessment of the cost-effectiveness of this approach in future studies is warranted.

Abbreviations

CRD: 

component-resolved diagnosis

nsLTPs: 

non-specific lipid transfer proteins

SPT: 

skin prick test

Declarations

Authors’ contributions

GTP conceived and designed the study, performed the analysis, interpreted the data, and was a major contributor in writing the manuscript. All authors participated in data collection, and thoroughly revised the various drafts of the manuscript. All authors read and approved the final manuscript.

Acknowledgements

The authors would like to thank Fernando de la Torre for thoroughly revising the manuscript text, and BioClever2005 S.L. for providing statistical and medical writing support.

This was a cross-sectional study of consecutive patients admitted to the otorhinolaryngology department of three hospitals in the Balearic Islands (Spain) due to symptoms of respiratory allergy between October 2012 and November 2013.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The study protocol was approved by the independent Ethics Committee of the Balearic Islands. All patients signed an informed consent to participate in this study.

Funding

The study was partially funded by ALK-abelló S.A., who afforded the statistical support.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Otorhinolaryngology, Hospital Universitario Son Espases, Palma de Mallorca, Spain
(2)
Department of Otorhinolaryngology and Allergology, Clínica Juaneda, Palma de Mallorca, Spain

References

  1. Dahl R, Andersen PS, Chivato T, Valovirta E, de Monchy J. National prevalence of respiratory allergic disorders. Respir Med. 2004;98:398–403. https://doi.org/10.1016/j.rmed.2003.11.015.View ArticlePubMedGoogle Scholar
  2. Simoens S. The cost-effectiveness of immunotherapy for respiratory allergy: a review. Allergy Eur J Allergy Clin Immunol. 2012;67:1087–105. https://doi.org/10.1111/j.1398-9995.2012.02861.x.View ArticleGoogle Scholar
  3. Meltzer EO, Bukstein DA. The economic impact of allergic rhinitis and current guidelines for treatment. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. 2011;106:S12–6. https://doi.org/10.1016/j.anai.2010.10.014.View ArticleGoogle Scholar
  4. Bousquet PJ, Burbach G, Heinzerling LM, Edenharter G, Bachert C, Bindslev-Jensen C, et al. GA2LEN skin test study III: minimum battery of test inhalent allergens needed in epidemiological studies in patients. Allergy Eur J Allergy Clin Immunol. 2009;64:1656–62. https://doi.org/10.1111/j.1398-9995.2009.02169.x.View ArticleGoogle Scholar
  5. Roberts G, Peckitt C, Northstone K, Strachan D, Lack G, Henderson J, et al. Relationship between aeroallergen and food allergen sensitization in childhood. Clin Exp Allergy J Br Soc Allergy Clin Immunol. 2005;35:933–40. https://doi.org/10.1111/j.1365-2222.2005.02280.x.View ArticleGoogle Scholar
  6. Ferreira F, Wolf M, Wallner M. Molecular approach to allergy diagnosis and therapy. Yonsei Med J. 2014;55:839–52. https://doi.org/10.3349/ymj.2014.55.4.839.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Sastre J, Landivar ME, Ruiz-García M, Andregnette-Rosigno MV, Mahillo I. How molecular diagnosis can change allergen-specific immunotherapy prescription in a complex pollen area. Allergy Eur J Allergy Clin Immunol. 2012;67:709–11. https://doi.org/10.1111/j.1398-9995.2012.02808.x.View ArticleGoogle Scholar
  8. Letrán A, Espinazo M, Moreno F. Measurement of IgE to pollen allergen components is helpful in selecting patients for immunotherapy. Ann Allergy Asthma Immunol. 2013;111:295–7. https://doi.org/10.1016/j.anai.2013.07.005.View ArticlePubMedGoogle Scholar
  9. Lepage-Nefkens I, Van der Maas M, Rijnen M, Hermansson L. A cost-effectiveness model evaluating component-resolved diagnosis (Crd) versus standard testing method (Skin Prick Testing (Spt)) in the diagnosis and treatment of allergic rhinitis in the Netherlands. Value Health. 2015;18:A359. https://doi.org/10.1016/j.jval.2015.09.689.View ArticlePubMedGoogle Scholar
  10. Kazemi-Shirazi L, Niederberger V, Linhart B, Lidholm J, Kraft D, Valenta R. Recombinant marker allergens: diagnostic gatekeepers for the treatment of allergy. Int Arch Allergy Immunol. 2002;127:259–68. https://doi.org/10.1159/000057742.View ArticlePubMedGoogle Scholar
  11. Melioli G, Passalacqua G, Canonica GW, Baena-Cagnani CE, Matricardi P. Component-resolved diagnosis in pediatric allergic rhinoconjunctivitis and asthma. Curr Opin Allergy Clin Immunol. 2013;13:446–51. https://doi.org/10.1097/ACI.0b013e32836274d8.View ArticlePubMedGoogle Scholar
  12. Van Gasse AL, Mangodt EA, Faber M, Sabato V, Bridts CH, Ebo DG. Molecular allergy diagnosis: status anno 2015. Clin Chim Acta Int J Clin Chem. 2015;444:54–61. https://doi.org/10.1016/j.cca.2015.02.012.View ArticleGoogle Scholar
  13. Letrán A, Espinazo M, Moreno F. Measurement of IgE to pollen allergen components is helpful in selecting patients for immunotherapy. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. 2013;111:295–7. https://doi.org/10.1016/j.anai.2013.07.005.View ArticleGoogle Scholar
  14. Caballero Martínez F, Plaza V, Quirce Gancedo S, Fernández Benítez M, Gómez Ruiz F, López Viña A, et al. External assessment of the GEMA2009 recommendations by a multidisciplinary expert panel on asthma. Arch Bronconeumol. 2010;46:411–9. https://doi.org/10.1016/j.arbres.2010.05.004.View ArticlePubMedGoogle Scholar
  15. Executive Committee GEMA 2009. GEMA 2009 (Spanish guideline on the management of asthma). J Investig Allergol Clin Immunol. 2010;20(Suppl 1):1–59.Google Scholar
  16. Bousquet J, Schünemann HJ, Samolinski B, Demoly P, Baena-Cagnani CE, Bachert C, et al. Allergic rhinitis and its impact on asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol. 2012;130:1049–62. https://doi.org/10.1016/j.jaci.2012.07.053.View ArticlePubMedGoogle Scholar
  17. Dreborg S. Skin testing. The safety of skin tests and the information obtained from using different methods and concentrations of allergen. Allergy. 1993;48:473–5.View ArticleGoogle Scholar
  18. Petersen AB, Gudmann P, Milvang-Grønager P, Mørkeberg R, Bøgestrand S, Linneberg A, et al. Performance evaluation of a specific IgE assay developed for the ADVIA centaur immunoassay system. Clin Biochem. 2004;37:882–92. https://doi.org/10.1016/j.clinbiochem.2004.06.010.View ArticlePubMedGoogle Scholar
  19. Lizaso MT, García BE, Tabar AI, Lasa E, Echechipía S, Lvarez MJ, et al. Comparison of conventional and component-resolved diagnostics by two different methods (Advia-Centaur/Microarray-ISAC) in pollen allergy. Ann Allergy Asthma Immunol. 2011;107:35–41. https://doi.org/10.1016/j.anai.2011.03.017.View ArticlePubMedGoogle Scholar
  20. Orovitg A, Guardia P, Barber D, de la Torre F, Rodríguez R, Villalba M, et al. Enhanced diagnosis of pollen allergy using specific immunoglobulin E determination to detect major allergens and panallergens. J Investig Allergol Clin Immunol. 2011;21:253–9.PubMedGoogle Scholar
  21. Boi M, Llorens L. Annual pollen spectrum in the air of Palma de Mallorca (Balearic Islands, Spain). Aerobiologia. 2013;29:385–97. https://doi.org/10.1007/s10453-013-9288-0.View ArticleGoogle Scholar
  22. Barber D, de la Torre F, Feo F, Florido F, Guardia P, Moreno C, et al. Understanding patient sensitization profiles in complex pollen areas: a molecular epidemiological study. Allergy. 2008;63:1550–8. https://doi.org/10.1111/j.1398-9995.2008.01807.x.View ArticlePubMedGoogle Scholar
  23. Pfaar O, Demoly P, Gerth van Wijk R, Bonini S, Bousquet J, Canonica GW, et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI position paper. Allergy. 2014;69:854–67. https://doi.org/10.1111/all.12383.View ArticlePubMedGoogle Scholar
  24. Wahn U. Preventing new sensitization and asthma onset by allergen immunotherapy: the current evidence. Curr Opin Allergy Clin Immunol. 2017;17:443–6. https://doi.org/10.1097/ACI.0000000000000399.View ArticlePubMedGoogle Scholar
  25. Petalas K, Durham SR. Allergen immunotherapy for allergic rhinitis. Rhinology. 2013;51:99–110. https://doi.org/10.4193/Rhino12.086.View ArticlePubMedGoogle Scholar
  26. Cipriani F, Mastrorilli C, Tripodi S, Ricci G, Perna S, Panetta V, et al. Diagnostic relevance of IgE sensitization profiles to eight recombinant Phleum pratense molecules. Allergy. 2018;73:673–82. https://doi.org/10.1111/all.13338.View ArticlePubMedGoogle Scholar
  27. Segura N, Abos T, Compaired JA, Compés E, Guallar I, Morales M, et al. Influence of profilin on sensitisation profiles determined by cutaneous tests and IgE to major allergens in polysensitised patients. Clin Transl Allergy. 2016;6:23. https://doi.org/10.1186/s13601-016-0114-y.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s) 2019

Advertisement

Clinical and Molecular Allergy

ISSN: 1476-7961

Contact us